The future standard
for brucellosis vaccines

GreenVac technology will revolutionise efficiency and standardisation in brucellosis control programs


BGV1 is a remarkable vaccine, that is:

  • New (under patent)
  • Obtained by Rev1 gene deletion
  • Consists of living bacteria
  • Hightly attenuated
  • Immunogenic & effective against infection


Replaces Rev1, since BGV1 is:

  • Safe, including with pregnant animals in mass vaccination
  • Protective
  • Compatible with D.I.V.A.
  • Treatable with antibiotics
  • Aplicable for uncomplicated control & eradication programmes
  • Cost-effective, reducing financial impact in Public Health

Potential Unique Selling Point, to:-

Transform the lives of 600 million livestock holders in developing countries

Follow us and stay up to date with our news